A5080497221- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Pancreatitis Pathology and Treatment
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Signaling Pathways in Disease
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Kruppel-like factors research
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Caveolin-1 and cellular processes
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- TGF-β signaling in diseases
- Pancreatic function and diabetes
- Phagocytosis and Immune Regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastroesophageal reflux and treatments
- Protease and Inhibitor Mechanisms
- Gastrointestinal disorders and treatments
- Gastric Cancer Management and Outcomes
- Cancer Research and Treatments
- Immune cells in cancer
Philipps University of Marburg
2016-2025
Universitätsklinikum Gießen und Marburg
2016-2025
Charité - Universitätsmedizin Berlin
2006-2022
Statens Serum Institut
2022
European Neuroendocrine Tumor Society
2010-2021
Klinikum rechts der Isar
2006-2020
University Hospital Magdeburg
2020
Technical University of Munich
2010-2020
Target (Germany)
2020
German Marine Research Consortium
2020
Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin to the growth well-differentiated metastatic NETs is a matter debate. We performed placebo-controlled, double-blind, phase IIIB study midgut NETs. hypothesis was that octreotide LAR prolongs time tumor progression and survival.Treatment-naive were randomly assigned either placebo or 30 mg intramuscularly monthly intervals until death....
Autoimmune pancreatitis (AIP) is a treatable form of chronic that has been increasingly recognised over the last decade. We set out to better understand current burden AIP at several academic institutions diagnosed using International Consensus Diagnostic Criteria, and describe long-term outcomes, including organs involved, treatments, relapse frequency sequelae.23 from 10 different countries participated in this multinational analysis. A total 1064 patients meeting Criteria for type 1...
The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for management individuals with increased risk pancreatic cancer based on family history or germline mutation status (high-risk individuals).A modified Delphi approach was employed reach among a multidisciplinary group experts who voted statements. Consensus considered reached if ≥75% agreed disagreed.Consensus 55 main goals surveillance (to identify high-grade dysplastic...
however, is covered in this chapter, since early recognition and treatment important for complication of carcinoid syndrome.Since highly proliferative carcinomas with a neuroendocrine phenotype but poor histological differentiation grade are extremely rare the jejuno-ileum, management such cases remains individual can currently not be considered standardised according to organ-oriented guidelines.For cases, reader referred previous guidelines [4] .This therefore, deals non-metastatic NEN...
Abstract Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show short-chain fatty acids (SCFAs) pentanoate and butyrate enhance anti-tumor cytotoxic T lymphocytes (CTLs) chimeric antigen receptor (CAR) through metabolic epigenetic reprograming. We in vitro treatment CTLs CAR with increases function mTOR as a central cellular sensor, inhibits class I histone deacetylase activity. This reprogramming results elevated production...
The field of pancreatic stellate cell (PSC) biology is very young, as the essential in-vitro tools to study these cells (ie, methods isolate and culture PSC) were only developed recently in 1998. Nonetheless, there has been an exponential increase research output this over past decade, with numerous groups around world focusing their energies into elucidating function cells. It now well established that PSC are responsible for producing stromal reaction (fibrosis) two major diseases...
Background: Somatostatin analogs have been shown to control the growth of well-differentiated metastatic neuroendocrine tumors. Their effect on overall survival is a matter debate. We analyzed prognostic significance early treatment with octreotide LAR and hepatic tumor load in PROMID trial cohort. Patients Methods: Between 2001 2008, 85 treatment-naïve patients were randomly assigned monthly 30 mg or placebo until progression death. Post-study was at discretion investigator. Upon disease...
Bei diesem Dokument handelt es sich um die aktualisierte Fassung der 2006 erstmals erstellten S3-Leitlinie zum exokrinen Pankreaskarzinom.
Macroautophagy is an evolutionarily conserved cellular process involved in the clearance of proteins and organelles. Although cytoplasmic machinery that orchestrates autophagy induction during starvation, hypoxia, or receptor stimulation has been widely studied, key epigenetic events initiate maintain remain unknown. Here we show methyltransferase G9a coordinates transcriptional activation regulators autophagosome formation by remodeling chromatin landscape. Pharmacological inhibition RNA...
Objective Desmoplasia and hypovascularity are thought to impede drug delivery in pancreatic ductal adenocarcinoma (PDAC). However, stromal depletion approaches have failed show clinical responses patients. Here, we aimed revisit the role of tumour microenvironment as a physical barrier for gemcitabine delivery. Design Gemcitabine metabolites were analysed LSL-Kras G12D/+ ; LSL-Trp53 R172H/+ Pdx-1-Cre (KPC) murine tumours matched liver metastases, primary cell lines, cancer-associated...
Pancreatic ductal adenocarcinoma (PDAC) is characterised by an abundant desmoplastic stroma composed of cancer-associated fibroblasts (CAF) and interspersed immune cells. A non-canonical CD8
<h3>Objective:</h3> Familial pancreatic cancer (FPC) accounts for approximately 3% of all (PC) cases. It has been suggested that high-risk individuals (HRIs) should be offered a screening programme. <h3>Aim:</h3> To evaluate the diagnostic yield prospective programme in HRIs from families with FPC over period 5 years. <h3>Methods:</h3> National German Pancreatic Cancer Registry (FaPaCa) were counselled and enrolled prospective, board-approved PC Screening included clinical examination,...